Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2207390 | 0.79 | NTRK1 (0.44) | SMN1; SMN2KMT2AHTTLMNAMEN1 | |
| SCHEMBL2211363 | 0.79 | HRH4 (0.38) | SMN1; SMN2KMT2AHTTLMNAMEN1 | |
| SCHEMBL2212117 | 0.79 | HRH4 (0.38) | SMN1; SMN2KMT2AHTTLMNAMEN1 | |
| SCHEMBL2512128 | 0.79 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2AHTTLMNAMEN1 | |
| SCHEMBL2211405 | 0.79 | APP (0.42) | ROCK1 | |
| SCHEMBL2243249 | 0.79 | MAT2A (0.37) | SMN1; SMN2KMT2AHTTLMNAMEN1 | |
| SCHEMBL2211885 | 0.77 | NTRK1 (0.40) | CYP1A2CYP2C19CYP2C9CYP2D6MKNK1 | |
| SCHEMBL2208325 | 0.77 | APP (0.42) | LMNACYP1A2CYP2C19MAPTCYP3A4 | |
| SCHEMBL2212445 | 0.77 | IGF1R (0.46) | SMN1; SMN2KMT2AHTTLMNAMEN1 | |
| SCHEMBL2210092 | 0.77 | IGF1R (0.37) | SMN1; SMN2KMT2AHTTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245252-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | claimed |
| US-20110245252-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-7982033-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245252-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | SMN1; SMN2 3634/4885KMT2A 2698/4885HTT 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.